Mehmet Emin ERDAL, Tuba GÖKDOĞAN EDGÜNLÜ, Seval KUL, Aynur ÖZGE, Osman Özgür YALIN

A Study of the Impact of Death Receptor 4 (DR4) Gene Polymorphisms in Alzheimer's Disease

Background:Excessive apoptosis is believed to play a role in many degenerative and non-degenerative neurological diseases including Alzheimer's disease (AD). Much recent data suggest that apoptotic mechanisms may represent the missing link between A? deposition and proteolysis of tau protein. However, there is emerging evidence that apoptotic mechanisms may play a role in Alzheimer's Disease pathogenesis in the absence of overt apoptosis. TNF-related apoptosis inducing ligand receptor 1 (Death Receptor 4, DR4) might impair the apoptotic signal transduction and lead to dysregulation of the homeostasis between cell survival and cell death.Aims: The aim of our study was to further investigate the relationship between genetic variants of DR4 and Alzheimer's Disease. Study Design:Case control study. Methods: Sixty-eight patients with AD were included in the study. The control group comprised 72 subjects without signs of neurodegenerative diseases, as evidenced by the examination.DNA was extracted from whole blood using the salting-out procedure. Genotypes were identified by restriction fragment length polymorphism analysis of polymerase chain reaction (PCR-RFLP) products.Results: We observed significant differences in the genotypic distribution of the rs6557634 polymorphism in AD patients compared with controls (p0.05). According to haplotype analysis of the DR4 gene for rs6557634, rs20575 and rs20576 polymorphisms, GCA and GCC haplotypes might be a risk factor for AD. Also, we have shown that ACA, GGC and GGA haplotypes might be protective factors against AD.Conclusion: The present results indicate for the first time the possible contribution of the DR4 gene rs6557634, rs20575, rs20576 polymorphisms in Alzheimer's Disease, which may influence susceptibility to Alzheimer's Disease.

PDF

___

1. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, et al. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry 2006;63:168-74. [CrossRef]
2. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.
3. Suzuki T, Araki Y, Yamamoto T, Nakaya T. Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J Biochem 2006;139:949-55. [CrossRef]
4. Sorrentino G, Bonavita V. Neurodegeneration and Alzheimer's disease: the lesson from tauopathies. Neurol Sci 2007;28:63-71. [CrossRef]
5. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998;281:1305-8. [CrossRef]
6. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60. [CrossRef]
7. Wu CK, Thal L, Pizzo D, Hansen L, Masliah E, Geula C. Apoptotic signals within the basal forebrain cholinergic neurons in Alzheimer's disease. Exp Neurol 2005;195:484-96. [CrossRef]
8. Graham RK, Ehrnhoefer DE, Hayden MR. Caspase-6 and neurodegeneration. Trends Neurosci 2011:34;646-56. [CrossRef]
9. Jin Z, El-Deiry WS. Overview of cell death signaling pathways. Cancer Biol Ther 2005;4:139-63. [CrossRef]
10. Kuwano R, Miyashita A, Arai H, Asada T, Imagawa M, Shoji M, et al. Dynamin-binding protein gene on chromosome 10q is associated with late-onset Alzheimer's disease. Hum Mol Genet 2006;15:2170-82. [CrossRef]
11. Anel A, Bosque A, Naval J, Pineiro A, Larrad L, Alava MA, et al. Apo2L/TRAIL and immune regulation. Front Biosci 2007;12: 2074-84. [CrossRef]
12. Lukiw WJ, Bazan NG. Survival signalling in Alzheimer's disease. Biochem Soc Trans 2006;34:1277-82. [CrossRef]
13. Cantarella G, Uberti D, Carsana T, Lombardo G, Bernardini R, Memo M. Neutralization of TRAIL death pathway protects human neuronal cell line from ?-amyloid toxicity. Cell Death Differ 2003;10:134-41. [CrossRef]
14. Uberti D, Cantarella G, Facchetti F, Cafici A, Grasso G, Bernardini R, et al. TRAIL is expressed in the brain cells of Alzheimer's disease patients. Neuroreport 2004;15:579-581. [CrossRef]
15. Uberti D, Ferrari-Toninelli G, Bonini SA, Sarnico I, Benarese M, Pizzi M, et al. Blockade of the tumor necrosis factor-related apoptosis inducing ligand death receptor DR5 prevents beta-amyloid neurotoxicity. Neuropsychopharmacology 2007;32:872-80. [CrossRef]
16. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;19:981-9. [CrossRef]
17. McKhann G, Drachman D, Foltein M, Katzman R, Price D, Stadlen EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44. [CrossRef]
18. Li Z, Zhang Z, He Z. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn). Cell Res 2009;19:519-23. [CrossRef]
19. Dörr J, Bechmann I, Waiczies S, Aktas O, Walczak H, Krammer PH, et al. Lack of tumor necrosis factor-related apoptosis-inducing ligand but presence of its receptors in the human brain. J Neurosci 2002;15:22-4.
20. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, et al. Human brain-cell death induced by tumournecrosis- factor-related apoptosis-inducing ligand (TRAIL). Lancet 2000;356: 827-8. [CrossRef]
21. Koksal IT, Sanlioglu AD, Karacay B, Griffith TS, Sanlioglu S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostatespecific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008;26:158-65. [CrossRef]
22. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B, et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007;69:716-23. [CrossRef]
23. Genc S, Egrilmez MY, Yaka E, Cavdar Z, Iyilikci L, Yener G, et al. TNF-related apoptosis-inducing ligand level in Alzheimer's disease. Neurol Sci 2009;30:263-7. [CrossRef]
24. Isi H, Erdal ME, Akdeniz S, Oral D, Ay OI, Tekes S, et al. The Tumor necrosis factor-? (TNF-?) gene -308 G/A polymorphism and the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene polymorphisms in Behcet's disease. Biotechnol & Biotechnol 2010;24:3.
25. Isi H, Oral D, Yildiz T, Ates G, Sinir C, Ay OI, et al. The tumor necrosis factor-? -308 G/A polymorphism and the tumor necrosis factor-related apoptosis-inducing ligand polymorphisms, in asthmatic patients and healthy subjects. Biotechnol & Biotechnol 2010;24:1.
26. Chen B, Liu S, Wang XL, Xu W, Li Y, Zhao WH, et al. TRAIL-R1 polymorphisms and cancer susceptibility: an evidence-based metaanalysis. Eur J Cancer 2009;45:2598-605. [CrossRef]
27. Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005;167:170-4. [CrossRef]